Vaxxinity(OTC) VAXX

Current Price$0.00

Market Cap$14.10K

Since IPO (2021)-100%

5 YearN/A

1 Year-100%

1 Month+9,900%

Vaxxinity last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-24

Vaxxinity stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-17
1 month	+9,900%	USD 0.00	2026-06-24
3 month	+9,900%	USD 0.00	2026-04-24
Year to date	-66.67%	USD 0.00	2025-12-31
1 year	-99.77%	USD 0.04	2025-07-24
3 year	-100%	USD 2.56	2023-07-25
Since inception	-100%	USD 16.55	2021-11-11

Vaxxinity Financials at a Glance

Market Cap

$14.10K

Revenue (TTM)

$0.00

Net Income (TTM)

-$56.94M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

100

Open

$0.06

Price

$0.00

Volume

100

Open

$0.06

Previous Close

$0.00

Daily Range

$0.00 - $0.06

52-Week Range

$0.00 - $0.20

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

100

Open

$0.06

Previous Close

$0.00

Daily Range

$0.00 - $0.06

52-Week Range

$0.00 - $0.20

Estimated Earnings Date

Aug 12, 2026

VAXX News

scientists examine cell make up microscope biotech

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vaxxinity

Vaxxinity, Inc. is a biotechnology company focused on developing innovative therapeutic candidates for neurological disorders and infectious diseases. Founded in 2014 and headquartered in Dallas, Texas, the company aims to address significant health challenges, particularly those related to coronaviruses and neurodegenerative conditions.

Products and Services

UB-311: Phase 2 candidate targeting Alzheimer's disease
UB-312: Investigational therapy for Parkinson's disease in Phase 1 trials
UB-612: Phase 3 candidate designed to neutralize SARS-CoV-2

Growth Outlook

Strong pipeline with multiple candidates in various clinical stages
Focus on high-demand therapeutic areas, including Alzheimer's and COVID-19
Potential for strategic partnerships to enhance development capabilities

Financial Highlights

Recent quarterly net income of -$11.39 million, reflecting ongoing R&D investments
Cash and short-term investments totaled $30.4 million as of Q4 2023
Operating expenses of $11.69 million in Q4 2023, indicating significant R&D focus

Vaxxinity, Inc. is positioned in a critical sector of healthcare, with a robust pipeline aimed at addressing pressing medical needs. The company's focus on neurological disorders and infectious diseases aligns with growing market demands, particularly in the wake of the COVID-19 pandemic. Recent financial data indicates a commitment to research and development, with substantial investments aimed at advancing clinical trials. The company’s cash reserves provide a buffer for ongoing operations and development efforts, while the potential for strategic partnerships could further enhance its growth trajectory. Overall, Vaxxinity represents an intriguing opportunity within the biotechnology landscape.

AI Generated • Jul 8, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Mei Mei Hu

Website

www.vaxxinity.com

Headquarters

Dallas, TX 75201, US

VAXX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-0.15%

Return on Capital

-203.96%

Return on Assets

-0.13%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.10K

Shares Outstanding

140.66M

Volume

100

Avg. Volume

10.81K

Financials (TTM)

Gross Profit

-$2.23M

Operating Income

-$58.33M

EBITDA

-$54.01M

Operating Cash Flow

-$57.24M

Capital Expenditure

-$803.00K

Free Cash Flow

-$58.04M

Cash & ST Invst.

$30.40M

Total Debt

$15.17M

Vaxxinity Performance Analysis

Vaxxinity annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 66,000	N/A
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A

Vaxxinity sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2023-03-31	N/A
Q2	2023-06-30	N/A
Q3	2023-09-30	N/A
Q4	2023-12-31	N/A

Vaxxinity annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -1.09	N/A
2022	2022-12-31	USD -0.60	-45.4%
2023	2023-12-31	USD -0.45	-24.7%

Vaxxinity sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2023-03-31	6.3%
Q2	2023-06-30	26.7%
Q3	2023-09-30	9.1%
Q4	2023-12-31	10.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$456.00K

+15.6%

Gross Margin

0.00%

N/A

Market Cap

$14.10K

N/A

Market Cap/Employee

$247.37

N/A

Employees

N/A

Net Income

-$11.39M

+44.4%

EBITDA

-$10.75M

+45.3%

Quarterly Fundamentals

Name

Q4 2023YOY CHG

Total Cash

$30.40M

-65.0%

Total Debt

$15.17M

+4.3%

Accounts Receivable

$414.00K

+0.0%

Inventory

$0.00

-100.0%

Long Term Debt

$13.26M

+1.7%

Short Term Debt

$1.91M

+26.7%

Return on Assets

-0.13%

N/A

Return on Invested Capital

-2.18%

N/A

Free Cash Flow

-$12.26M

+17.0%

Operating Cash Flow

-$11.85M

+18.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

QBIOQ BioMed Inc.

QBIOQ BioMed Inc.$0.00-0.00%

SDCCQSmileDirectClub Inc Class A

SDCCQSmileDirectClub Inc Class A$0.00+0.00%

HLUNHEALTHeUNIVERSE, Inc.

HLUNHEALTHeUNIVERSE, Inc.$0.00+0.00%

TRVNTrevena, Inc.

TRVNTrevena, Inc.$0.01+0.00%

NNLXNanoLogix, Inc.

NNLXNanoLogix, Inc.$0.00+0.00%

INFIQInfinity Pharmaceuticals, Inc.

INFIQInfinity Pharmaceuticals, Inc.$0.00+0.00%

XSNXNovAccess Global Inc.

XSNXNovAccess Global Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

TAT&T

TAT&T$24.13+0.05%

FFord Motor Company

FFord Motor Company$14.37+0.02%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About VAXX

What is the current price of Vaxxinity?

Vaxxinity is trading at $0.00 per share.

What is the 52-week range for Vaxxinity?

Over the past 52 weeks, Vaxxinity has traded between $0.00 and $0.20.

How much debt does Vaxxinity have?

As of the most recent reporting period, Vaxxinity reported total debt of $15.17M.

How much cash does Vaxxinity have on hand?

Vaxxinity reported $5.04M in cash and cash equivalents in its most recent financial results.

What is Vaxxinity’s dividend yield?

Vaxxinity does not currently have a dividend yield.

Vaxxinity(OTC) VAXX

Vaxxinity Financials at a Glance

VAXX News

Why Shares of Vaxxinity Jumped This Week

Why Shares of Vaxxinity Soared This Week

Vaxxinity Has a Rough Public Debut

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Vaxxinity

VAXX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Vaxxinity Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About VAXX

What is the current price of Vaxxinity?

What is the 52-week range for Vaxxinity?

How much debt does Vaxxinity have?

How much cash does Vaxxinity have on hand?

What is Vaxxinity’s dividend yield?

Premium Investing Services